Viktor Grünwald, MD, PhD | Authors

Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCC

June 05, 2021

CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.